A Phase III Trial of Maintenance Daily Oral VP-16 vs no Further Therapy Following Induction Chemotherapy with VP-16 plus Ifosfamide plus Cisplatin (VIP) in Extensive Small Cell Lung Cancer

Abstracts/Posters/Presentations:

• Ansari R, Loehrer PJ, Gonin R, Wasielewski MJ, Einhorn LH. A Phase III Study of VP16 plus Cisplatin (VP) alone or with Ifosfamide (VIP) in Previously Untreated Patients with Extensive Small Cell Carcinoma of the Lung (SCLC): A Hoosier Oncology Group and Walther Cancer Institute Trial LUN93-2. Slide presentation accepted to the ASCO Meeting, May 14-17th, 1994, Dallas, Texas.
• Sandler AB, Ansari R, Fisher W, Gonin R, Levy R, Einhorn LH. A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC). A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial LUN93-2. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.
• Sandler A, Ansari R, Saxman S, Walker P, Wasielewski MJ, Monaco F, Hayes J, Einhorn LH. Phase III Trial of Maintenance Daily Oral VP-16 Versus No Further Therapy Following Induction Chemotherapy With VP-16 (V) Plus Ifosfamide (I) Plus Cisplatin (P) (VIP) In Extensive Small Cell Lung Cancer (SCLC): A Hoosier Oncology Group (HOG) Trial LUN93-2. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA
• Nasser H. Hanna, Alan B. Sandler, Patrick J. Loehrer, Sr., Rafat Ansari, Sin-Ho Jung, Kathleen Lane and Lawrence H. Einhorn Maintenance Daily Oral Etoposide Versus No Further Therapy Following Induction Chemotherapy With Etoposide Plus Ifosfamide Plus Cisplatin In Extensive Small Cell Lung Cancer: A Hoosier Oncology Group Study LUN93-2. Accepted as a poster presentation with discussion for ASCO annual meeting May 12-15, 2001, San Francisco, CA. Proc Am Soc Clin Oncol 20: 2001 (abstr 1261)

Manuscripts/Articles:

• Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH: Cisplatin Plus Etoposide With and Without Ifosfamide in Extensive Small-Cell Lung Cancer: A Hoosier Oncology Group Study LUN93-2. J Clin Oncol 13:2594-2599, 1995
• Hanna NH, Sandler AB, Loehrer PJ Sr, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002 Jan;13(1):95-102. See abstract.